Pharming Group’s Joenja® receives FDA approval for the treatment of rare APDS condition in Adults and Pediatric patients
Pharming Group N.V. has received FDA approval for Joenja® (leniolisib) to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and above. Joenja® is a selective ...